N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children
Open Access
- 30 January 2015
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 100 (6), 521-526
- https://doi.org/10.1136/archdischild-2014-306795
Abstract
Objective N-methyl-D-aspartate receptor antibody (NMDAR-Ab) encephalitis is a well-recognised clinico-immunological syndrome that presents with neuropsychiatric symptoms cognitive decline, movement disorder and seizures. This study reports the clinical features, management and neurological outcomes of paediatric NMDAR-Ab-mediated neurological disease in the UK. Design A prospective surveillance study. Children with NMDAR-Ab-mediated neurological diseases were voluntarily reported to the British Neurological Surveillance Unit (BPNSU) from November 2010 to December 2011. Initial and follow-up questionnaires were sent out to physicians. Results Thirty-one children fulfilled the criteria for the study. Eight presented during the study period giving an incidence of 0.85 per million children per year (95% CI 0.64 to 1.06); 23 cases were historical. Behavioural change and neuropsychiatric features were present in 90% of patients, and seizures and movement disorders both in 67%. Typical NMDAR-Ab encephalitis was reported in 24 children and partial phenotype without encephalopathy in seven, including predominantly psychiatric (four) and movement disorder (three). All patients received steroids, 22 (71%) received intravenous immunoglobulin, 9 (29%) received plasma exchange,and 10 (32%) received second-line immunotherapy. Of the 23 patients who were diagnosed early, 18 (78%) made a full recovery compared with only 1 of 8 (13%) of the late diagnosed patients (p=0.002, Fisher's exact test). Seven patients relapsed, with four needing additional second-line immunotherapy. Conclusions Paediatric NMDAR-Ab-mediated neurological disease appears to be similar to adult NMDAR-Ab encephalitis, but some presented with a partial phenotype. Early treatment was associated with a quick and often full recovery.Keywords
This publication has 22 references indexed in Scilit:
- Anti–N-methyl-D-aspartate Receptor-Mediated Encephalitis in Infants and Toddlers: Case Report and Review of the LiteraturePediatric Neurology, 2014
- Herpes simplex virus encephalitis is a trigger of brain autoimmunityAnnals of Neurology, 2013
- N‐methyl‐D‐aspartate receptor antibody‐associated movement disorder without encephalopathyDevelopmental Medicine and Child Neurology, 2013
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigensJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Neuronal autoantigens—pathogenesis, associated disorders and antibody testingNature Reviews Neurology, 2012
- Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with Cyclophosphamide: The need for early aggressive immunotherapy in tumour negative paediatric patientsEuropean Journal of Paediatric Neurology, 2012
- Cognitive deficits following anti-NMDA receptor encephalitisJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Autoantibodies associated with diseases of the CNS: new developments and future challengesThe Lancet Neurology, 2011
- N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexesBrain, 2010